ONESOURCE1,548.10

Onesource Specialty Pharma Ltd.

· Pharma & Health
₹ CrorePeersSTARDIVISLABGLANDPFIZERPOLYMEDRAINBOWKIMSJUBLPHARMAMcap ₹17,744 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-0.31-1.27-1.27
Return on Assets-0.24-0.90-0.90
Return on Capital Employed2.990.370.37
Return on Invested Capital1.190.290.57
Margins
EBITDA Margin32.2921.4021.97
Operating Margin13.331.771.77
Incremental Operating Margin720.03
Pretax Margin-4.64-6.47-4.36
Net Income Margin-1.24-5.19-3.15
Net Income to Common Margin-5.19
FCF Margin-1.49-39.43-39.43
Additional
Effective Tax Rate74.2319.7527.72
Sustainable Growth Rate-0.31-1.27-1.27
Incremental Operating Margin %720.0325.40
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.